Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
15.73
-0.36 (-2.24%)
At close: Mar 28, 2025, 4:00 PM
15.30
-0.44 (-2.77%)
Pre-market: Mar 31, 2025, 9:02 AM EDT
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 342 employees as of December 31, 2024. The number of employees increased by 46 or 15.54% compared to the previous year.
Employees
342
Change (1Y)
46
Growth (1Y)
15.54%
Revenue / Employee
$574,684
Profits / Employee
-$409,471
Market Cap
1.87B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARQT News
- 4 days ago - Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 6 days ago - Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
- 24 days ago - Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting - GlobeNewsWire
- 25 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 4 weeks ago - Arcutis: ZORYVE Net Product Revenue Growth Isn't The Only Opportunity On Deck - Seeking Alpha
- 4 weeks ago - Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations - Seeking Alpha
- 4 weeks ago - U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis - GlobeNewsWire